Background and Aim: Regarding to paradoxical results of the studies about the effects of atorvastatin on inflammatory markers and metabolism, we aimed to evaluate the effects of atorvastatin on inflammatory markers in diabetic patients.
Materials and Methods: Through a double blind randomized clinical trial, placebo control, 88 type two diabetic patients (T2DP), were treated with anti-diabetes oral agents, were randomly classified into two 44 cases groups. The intervention group took atorvastatin 40 mg daily and control group took placebo for three months and adiponectin, hsCRP, leptin, TNF-α, lipid profile and fasting blood glucose (FBS) were measured and compared at the beginning and the end of the study. The data were analyzed using student t test and paired t test.
Findings: After three months, adiponectin was significantly increased in intervention group in comparison to control group, but leptin had not a significant change in two groups. Total cholesterol, hsCRP and LDL cholesterol (Low density Lipoprotein) were decreased significantly in the intervention group than control group, while FBS was
non-significantly decreased.
Conclusion: It seems atorvastatin is effective to decrease inflammatopry markers in diabetic patients.
